We hypothesize that confinement to the upper airways facilitates priming of the lungs with type I interferon (IFN-I), reducing viral replication elsewhere and decreasing the global systemic IFN-I response, which are requisite for the development of pernio. Yet the mechanism of IFN induction in pernio remains poorly understood. Although pernio is a hallmark manifestation of the interferonopathies, systemic treatment with IFN-I is insufficient for its development.

In our cohort, enrichment with IFN-mediated autoimmunity disorders supports the role of IFNs in pandemic-associated pernio. Close alignment with cold and propensity for relapses suggest a durable immune memory response. Ongoing translational investigation in this cohort will help to precisely elucidate the role of IFN-I, along with the genetic and immunological mechanisms that underlie pandemic-associated pernio.

Acknowledgments: We would like to thank our patients and families for their generous participation in this research. Figure 1 was created using available data from the National Weather Service (https://www.weather.gov) climate database and the Wisconsin Department of Health Services (https://www.dhs.wisconsin.gov) COVID-19 database.

Ashley T. Ng,1 John J. Moon,1 Olivia R. Steidl,2 Hailey Bussan,1 Jennifer M. Tran,1 George Luong,1 Aman Nihal,1 Meaghan Kenfield,1 Justin Frere,4 Benjamin R. TenOever,4 Ana C. Costa da Silva,5 Jacqueline W. Mays,3 Edward W. Cowen,6 Beth A. Drolet,1 Anne Marie Singh2 and Lisa M. Arkin1
1Department of Dermatology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; 2Division of Allergy & Immunology, Department of Pediatrics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; 3Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; 4Department of Microbiology, New York University, Langone Health, New York, NY 10016, USA; 5Oral Immunobiology Unit, NIDCR, NIH, Bethesda, MD, USA; and 6Department of Medicine, New York University, Langone Health, New York, NY 10016, USA.

Email: ang@dermatology.wisc.edu

A.T.N. and J.J.M. are joint first authors. A.M.S. and L.M.A. are joint last authors.

References

1 Freeman EE, McMahon DE, Lipoff JB et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83: 846–92.
2 Gehlhausen JR, Little AJ, Ko CJ et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2022; 119: e2122090119.
3 Hubiche T, Cardot-Leccia N, Le Duff F et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202–6.
4 Frumholtz L, Bouaziz JD, Battistella M et al. Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol 2021; 185: 1176–85.
5 Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003; 2: 119–25.
6 Moghadam P, Frumholtz L, Jaume L et al. Frequency of relapse and persistent cutaneous symptoms after a first episode of chilblain-like lesion during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2021; 35: e366–8.
7 Freeman EE, McMahon DE, Lipoff JB et al. Cold and COVID: recurrent pernio during the COVID-19 pandemic. Br J Dermatol 2021; 185: 214–16.
8 Sigal A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat Rev Immunol 2022; 22: 69–71.

Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system

DOI: 10.1111/bjd.21706

Dear Editor, Patients hospitalized with COVID-19 often have prolonged admissions and are frequently exposed to multiple medications, putting them at risk for adverse drug reactions including drug reaction with eosinophilia and systemic symptoms (DRESS). This study presents the largest reported case series of hospitalized patients with concurrent COVID-19 and DRESS syndrome.

A retrospective chart review was performed of 9330 polymerase chain reaction (PCR)-positive patients with COVID-19 and 144 cases of DRESS between 20 January 2020 and 20 May 2021. Patients with DRESS syndrome occurring concurrently with COVID-19 were assessed for clinical characteristics, culprit drugs, treatments and outcomes by a board-certified dermatologist and an allergist/immunologist. The RegiSCAR score was calculated for each patient using available documentation.1

The six confirmed cases of concurrent DRESS and COVID-19 (incidence 6.43 per 10 000 inpatients with COVID-19) were admitted to the intensive care unit and survived to discharge (Table 1). Their mean length of hospitalization was 68 days (SD 42; median 58). All patients developed
Table 1 Case descriptions of patients with concurrent drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and COVID-19

| Demographics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|--------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Age (years)  | 75        | 80        | 57        | 61        | 31        | 39        |
| Gender       | Male      | Male      | Female    | Male      | Female    | Female    |
| Comorbidities| DM, HTN, COPD | HTN, cancer, CAD | HTN, COPD | DM, HTN | Asthma | DM, asthma |

| Features of COVID-19 | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|----------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| COVID-19 symptoms    | SOB       | Cough, SOB, malaise | Cough, fever, SOB | Cough, SOB, malaise | Headache, fever, malaise | Cough, SOB, N/V, anosmia |
| Intubation           | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       |
| Intensive care unit  | Yes       | Yes       | Yes       | Yes       | Yes       | Yes       |
| Time from COVID-19 to admission (days) | 6 | 7 | 5 \(a\) | 23 \(a\) | 10 \(a\) | 9 \(a\) |

| Features of DRESS syndrome | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|----------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| RegiSCAR validation criteria | 3 (possible) | 4 (probable) | 7 (definite) | 8 (definite) | 4 (probable) | 7 (definite) |
| Naranjo score\(b\) | 7, 7 | 4, 4 | 10 | 7, 8 | 8, 8 | 7, 7 |

| Skin rash | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Extent (skin surface %) | 28\% | 26\% | 94\% | 52\% | Unknown | 100\% |
| Appearance | Morbilliform | Morbilliform | Morbilliform | Morbilliform | Morbilliform | Morbilliform |
| Onset (days from COVID-19 onset) | 25 | 46 | 13 | 42 | 39 | 17 |
| Onset (days from admission) | 19 | 39 | 8 \(a\) | 18 \(a\) | 29 \(a\) | 8 \(a\) |
| Onset (days from suspect drug initiation) | 13 | 34 | 8 | 15 | 26 | 6 |
| AEC peak \(\times 10^7 \text{cells L}^{-1}\) | 4-73 | 3-49 | 5-83 | 5-06 | 4-75 | 2-97 |
| Fever \((>38.5^\circ C)\) | Yes | Yes | Yes | Yes | Yes | Yes |
| Involved organs | Kidney | Liver, kidney | Liver, kidney | Liver, kidney | Liver, kidney | Liver, kidney |
| Potential culprit drugs\(c\) | Cefepime, vancomycin | Cefepime, vancomycin | Vancomycin | Cefepime, vancomycin | Vancomycin, meropenem | Cefepime, vancomycin |

| Virological studies | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 |
|---------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| Positive | COVID-19, HHV-6, HCV | COVID-19, HBV | COVID-19, HHV-6, HCV | COVID-19, CMV | COVID-19, HBV | COVID-19, HHV-6, HCV |
| Negative | HCV | HHV-6, HBV | EBV, CMV, HAV, HCV, HCV | CMV | HCV, HBV, HCV, HHV-6 | CMV, HHV-6, HCV |
| DRESS treatment | None | Methylprednisolone \((3 \text{mg kg}^{-1}) \times 2 \text{days, prednisone (1 mg kg}^{-1}) \times 25 \text{days}\) | Methylprednisolone \((1 \text{mg kg}^{-1}) \times 12 \text{days}\) | Methylprednisolone \((0.5 \text{mg kg}^{-1}) \times 19 \text{days}\) | Methylprednisolone \((1 \text{mg kg}^{-1}) \times 66 \text{days}\) | Methylprednisolone \((2 \text{mg kg}^{-1}) \times 21 \text{days}\) |
| Time to DRESS resolution (days) | 8 | 25 | 31 | 25 | 55 | 43 |

AEC, absolute eosinophil count; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CMV, cytomegalovirus; DM, diabetes mellitus; EBV, Epstein–Barr virus; HAV, hepatitis A; HBV, hepatitis B; HCV, hepatitis C; HHV, human herpesvirus; HSV, herpes simplex virus; HTN, hypertension; N/V, nausea/vomiting; SOB, shortness of breath; VZV, varicella zoster virus. \(a\)Based on admission date to an outside hospital. \(b\)The scores correspond in order to the drugs listed under ‘Potential culprit drugs’. \(c\)Based on provider assessment.
hypoxaemic respiratory failure and acute respiratory distress syndrome requiring endotracheal intubation. For the treatment of COVID-19 and/or empirical treatment for secondary bacterial pneumonia, treatment included vancomycin (100%), ceftipime (83%), corticosteroids (67%), remdesivir (50%), azithromycin (50%), hydroxychloroquine (50%), tocilizumab (50%) and meropenem (50%). The median times to rash onset from admission and from COVID-19 symptom onset were 19 days (range 8–39) and 32 days (range 13–46), respectively. The mean time to rash onset from probable culprit drug exposure was 17 days (range 6–34): this occurred at 0–7 days (17%), 8–14 days (33%) and > 15 days (50%). The most likely culprit drugs were vancomycin, ceftipime and meropenem. Because four patients (67%) were started on vancomycin and ceftipime concurrently, both drugs were considered probable culprits. The mean absolute eosinophil count was $4.47 \times 10^9$ cells L$^{-1}$ (range 2.97–5.83 $\times 10^9$). Cases had involvement of the kidney (100%) and liver (83%); all patients had mild troponin elevations that were not consistent with myocardial injury associated with DRESS syndrome. Five patients (83%) were treated with corticosteroids for a mean duration of 29 days, and one patient (17%) recovered without treatment.

Historically, the most commonly identified DRESS culprits from the literature include allopurinol, antiepileptics, sulfonamides and vancomycin. In this study, case of COVID-19 with DRESS were caused by antibiotics. In those with COVID-19 DRESS, hydroxychloroquine, vancomycin, piperacillin/tazobactam, ceftriaxone and azithromycin have previously been identified as culprits.1–3 Approximately 70% of patients with COVID-19 who are hospitalized receive antibiotics, but < 10% have secondary bacterial infections.4 Given that antibiotics are not the primary treatment of COVID-19 pneumonia but are instead often used empirically for a complicating bacterial pneumonia, improved measures to limit unnecessary antibiotic use in COVID-19 may prevent the development of DRESS.

The DRESS diagnostic criteria are notably similar to COVID-19 infection signs; for example, fever and/or multiorgan dysfunction may be due to either DRESS or COVID-19. However, skin rashes in response to viral infection (viral exanthems) typically present within 14 days of symptom onset.6 No patients included in the series had rash onset within 13 days from COVID-19 symptom onset, suggesting that the rash was drug induced and part of DRESS, and not the result of viral infection.

Notably, all patients in this study had markedly high eosinophilia, with most values peaking at more than $3.00 \times 10^9$ cells L$^{-1}$. This is despite use of corticosteroids in four patients (67%), who could have had lyed, masked or attenuated peripheral eosinophilia. The current data do not support that eosinophils play either a protective or pathogenic role in COVID-19 under normal circumstances.7 While the estimated mortality of DRESS syndrome is 5–10%, and the inhospital mortality from COVID-19 is 15.2–24.5%, none of the patients with DRESS and COVID-19 died in this study.

This study involved case finding through informatics methods for DRESS syndrome and COVID-19 PCR-positive testing. As such, we may not have captured all cases of both COVID-19 and DRESS concurrently. Data collection was retrospective, which may have resulted in missing or biased data. However, given that inpatient COVID-19 diagnosis and management were harmonized across our health system, we do not suspect misclassification.

It is not surprising that DRESS syndrome may occur in patients with COVID-19, given that patients are severely ill with long lengths of stay and antibiotic exposure. Patients with DRESS and COVID-19 had longer lengths of hospitalization than those with COVID-19 alone.8 Cases may be associated with significantly high eosinophil counts and multiorgan involvement, but may not be associated with worse outcomes from DRESS or COVID-19. It is necessary to expand this study over time, to different health systems and with longitudinal follow-up to assess long-term sequelae, to improve the characterization of DRESS in COVID-19.

Bethany Cucka1,8 Bianca Biglione1,8 Li Zhou,2,3 Elizabeth J. Phillips,4 Fatima Bassir,2 Upeka Samarakoon,6 Renajd Rraip1,8 Sidharth Chaud1,8 Liqin Wang,2,3 Santiago Alvarez-Arango,6,7 Kimberly G. Blumenthal5 and Daniela Kroshinsky1

1 Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA; 2 Division of General Internal Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 3 Harvard Medical School, Boston, MA, USA; 4 Center for Drug Safety and Immunology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 5 Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; 6 Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; and 7 Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Email: dkroshinsky@mgh.harvard.edu

B.C. and B.B. are joint first authors. K.G.B. and D.K. are joint senior authors.

References
1. Kardaun SH, Sidoroff A, Valeyrje-Allanore L et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609–11.
2. Ramirez E, Utro M, Rodriguez A et al. Incidence of suspected serious adverse drug reactions in corona virus disease-19 patients detected by a pharmacovigilance program by laboratory signals in a tertiary hospital in Spain: cautionary data. Front Pharmacol 2020; 11: 602841.
3. Ramirez GA, Della-Torre E, Tresoldi M et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19. Clin Microbiol Infect 2021; 27: 1190–2.
4. Cacoub P, Musette P, Descamps V et al. The DRESS syndrome: a literature review. Am J Med 2011; 124: 588–97.
Funding sources: this work was supported by the National Institutes of Health/National Institute of Allergy and Infectious Diseases, R01AI150295.

Conflicts of interest: K.G.B. receives grant funding from the National Institutes of Health/National Institute for Allergy and Infectious Diseases, and Agency for Healthcare Research and Quality; consulting fees from Weekley, Schulte, Valdes, Murman, Tonelli, Piedmont Liability Trust, and Vasios, Kelly & Strollo, PA; and royalties from UpToDate, outside the submitted work.

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.